劉鑫

1994—1998， 武漢大學，生命科學學院，本科生

2000—2005， 武漢大學，生命科學學院微生物專業，碩博連讀

2005—2008， 美國哈佛大學醫學院/貝斯以色列醫院，博士後 ^[1] 

2009—2016 武漢大學藥學院，副教授，

2016—至今， 教授，博士生導師 ^[1] 

（2018年獲得國家青年骨幹教師計劃支持，至美國華盛頓聖路易斯大學痛癢中心進行學術交流）

細胞生物學（本科生）

生理生化技術與現代藥學研究 （研究生，校級精品課程）

2012年 黃鶴英才

2014年 武漢大學藥學院青年教師講課比賽二等獎

2015年 湖北省優秀學士論文指導老師，武漢大學先進女職工

2016年 武漢大學醫學部突出貢獻獎

2017年 武漢大學教學成果獎二等獎（參與）

2018年 湖北省高等學校教學成果獎三等獎（參與）

主持項目：

1、國家自然科學基金面上項目(30971456)， 2011-2013年

2、國家自然科學基金青年項目(31400155)，2015-2017年

3、國家自然科學基金面上項目(81472550)，2015-2018年

4、武漢大學211人才項目，2010年

5、武漢大學醫學部種子基金，2014年

參與項目：

1、973項目子課題(2010CB529804), 2010-2015年

2、國家自然科學基金面上項目(81273540)，2013-2016年

3、國家自然科學基金原創探索專項項目(82151217)，2022-2024年

◆研究領域

腫瘤的血管生成調控機制

抗腫瘤藥物及相關機制研究

抗病毒藥物及相關機制研究

(1) Hou S#, Niu G#, Liu X#, Bourbon PM, Zhang D, Cui P, Zhao K, Zhao D, Zeng H. A novel transcriptional complex on the VE-cadherin promoter regulated the downregulation of VE-cadherin in the Down Syndrome Candidate Region 1 isoform 1L-mediated angiogenesis. Microvasc Res. 2021 Nov;138:104209. (#Co-first author) ^[1] 

(2) Xu J, Jiang Y, Wan L, Wang Q, Huang Z, Liu Y, Wu Y, Chen Z, Liu X*.Feeding Recombinant E. coli with GSTmBmKTX Fusion Protein Increases the Fecundity and Lifespan of Caenorhabditis elegans. Peptides. 2017 Jan. pii:S0196-9781(17)30008-6. (* Corresponding author) ^[1] 

(3) Chen L, Zhang J, Xu J, Wan L, Teng K, Xiang J, Zhang R, Huang Z, Liu Y, Li W, Liu X*. rBmαTX14 Increases the Life Span and Promotes the Locomotion of Caenorhabditis Elegans. PLoS One. 2016 Sep 9;11(9):e0161847. (* Corresponding author) ^[1] 

(4) Teng K,Deng C, Xu J, Men Q, Lei T, Di D, Liu T, Li W, Liu X*. Nuclear localization of TEF3-1 promotes cell cycle progression and angiogenesis in cancer. Oncotarget. 2016 Mar 22;7(12):13827-41. (* Corresponding author) ^[1] 

(5) Chen J, Zhang J, Xiang Y, Xiang L, Liu Y, He X, Zhou X, Liu X*, Huang Z*. Extracts of Tsai Tai (Brassica chinensis): enhanced antioxidant activity and anti-aging effects both in vitro and in Caenorhabditis elegans. Food &Function. 2016 Feb 17;7(2):943-52. (* Corresponding author ^[1]  )

(6) Yang F , Ai W, Jiang F, Liu X, Huang Z, Ai S, Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice. Journal of Pharmaceutical Sciences. 2016;105(2):639-649. ^[1] 

(7) Qiao C, Jiang Y, Deng C, Huang Z, Teng K, Chen L, Liu X*. Characterization of the transcriptional activation domains of human TEF3-1 (transcription enhancer factor 3 isoform 1). Arch Biochem Biophys. 2015 Mar 1;569:54-61. (* Corresponding author) ^[1] 

(8) Liu T, Men Q, Wu G, Yu C, Huang Z, Liu X*, Li W*. Tetrandrine induces autophagy and differentiation by activating ROS and Notch1 signaling in leukemia cells. Oncotarget.2015 Apr 10;6(10):7992-8006. (* Corresponding author) ^[1] 

(9) Wang H, Liu T, Li L, Wang Q, Yu C, Liu X*, Li W*. Tetrandrine is a potent cell autophagy agonist via activated intracellular reactive oxygen species. Cell Biosci. 2015 Jan 14;5:4. (* Corresponding author) ^[1] 

(10) Xiao W, Jiang Y, Men Q, Yuan L, Huang Z, Liu T, Li W, Liu X*. Tetrandrine induces G1/S cell cycle arrest through the ROS/Akt pathway in EOMA cells and inhibits angiogenesis in vivo. Int J Oncol.2015,46(1):360-8. (* Corresponding author) ^[1] 

(11) Liu X, Zhao D, James L, Li J, Zeng H. Requirement of the nuclear localization of transcription enhancer factor 3 for proliferation, migration, tube formation, and angiogenesis induced by vascular endothelial growth factor. FASEB J.2011, 25:1188-97. ^[1] 

(12) Liu X#, Zhao D#, Qin L, Li J, Zeng H.Transcription Enhancer Factor 3 (TEF3) Mediates the Expression of Down Syndrome Candidate Region 1 Isoform 1 (DSCR1-1L) in Endothelial Cells. J Biol Chem. 2008, 283:34159-67. (#Co-first author)(13) Qin L, Zhao D, Liu X, Nagy JA, Hoang MV, Brown LF, Dvorak HF, Zeng H.Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway. Mol Cancer Res. 2006 Nov;4(11):811-20. ^[1] 

(14) Liu X#, Zhou W#, Qi Y. Expression of SLAM (CDw150) on SF9 cell surface mediates Measles Viral infection in the nonpermissive cells through SLAM/MVH interaction. Microbes Infect. 2005,7:1235-45. (#Co-first author) ^[1] 

(15) Huang Y#, Liu X#, Dong L, Liu Z, He X, Liu W. Development of viral vectors for gene therapy for chronic pain. Pain Res Treat. 2011, 968218. doi: 10.1155/2011/968218 (#Co-first author) ^[1] 

(16) Yi C, Liu X, Liu Y, Lu S, Qi Y. Hemagglutinin protein of measles virus induces apoptosis of HeLa cells via bot extrinsic and intrinsic pathways. Can J Microbiol. 2013 , 59:814-24. ^[1] 

(17) Li J, Chen Y, Wan J, Liu X, Yu C, Li W. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21 (CIP1/WAF1) in human cancer cells. Br J Pharmacol. 2014 Jul;171(13):3182-95. ^[1] 

(18) Ai S, Jia T, Ai W, Duan J, Liu Y, Chen J, Liu X, Yang F, Tian Y, Huang Z. Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells. Br J Pharmacol. 2013 Apr;168(7):1719-35 ^[1] 

(19) Ai S, Duan J, Liu X, Bock S, Tian Y, Huang Z. Biological evaluation of a novel Doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Mol Pharm. 2011, 8:375-86. ^[1] 

(20) Li J, Chen Y, Wan J, Liu X, Yu C, Li W. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells. Br J Pharmacol. 2014 Jul; 171(13):3182-95. ^[1] 

(21) Mei L, Chen Y, Wang Z, Wang J, Wan J, Yu C, Liu X, Li W. Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21. Br J Pharmacol. 2015 May; 172(9):2232-45. ^[1]